Zobrazeno 1 - 10
of 254
pro vyhledávání: ''
Autor:
Tomoe Fujita, Yoshinobu Sasaki, Masaki Kawai, Mika Maeda, Jinhong Huang, Yuji Kumagai, Makoto Nagaoka, Toru Takenaka
Publikováno v:
Journal of Clinical Pharmacology
TAS‐303 (4‐piperidinyl 2,2‐diphenyl‐2‐[propoxy‐1,1,2,2,3,3,3‐d7] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a phys
Autor:
Edward M. Sellers, Li Shen Loo, Erin G Doty, Darren Wilbraham, Paul Berg, Max Tsai, Emily Liffick
Publikováno v:
Journal of Clinical Pharmacology
Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT1F) agonist under development as a novel therapy for acute treatment of migraine. A phase 1 randomized, placebo‐ and positive‐controlled cross
Autor:
Deanne Jackson Rudd, Charles Tomek, S. Aubrey Stoch, Patrick Larson, Andrea K. Schaeffer, Saijuan Zhang, Marian Iwamoto, Gillian Gillespie
Publikováno v:
Journal of clinical pharmacology. 62(2)
MK-8507 is an investigational HIV-1 nonnucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1 infection. MK-8507 contains 2 trifluoromethyl groups that may result in fluoride release through metabolism, but the extent o
Autor:
Etienne Ernault, Stefaan Rossenu, Jeike Biewenga, Sivi Ouwerkerk-Mahadevan, Wouter Willems, Ken Kurosawa, C. Kambili
Publikováno v:
Journal of Clinical Pharmacology
Based on the in vitro profile of bedaquiline against mycobacterial species, it is being investigated for clinical efficacy against pulmonary nontuberculous mycobacteria (PNTM). Being a cytochrome P450 3A substrate, pharmacokinetic interactions of bed
Publikováno v:
Journal of Clinical Pharmacology
A combination of olanzapine and samidorphan was recently approved by the US Food and Drug Administration for the treatment of patients with schizophrenia or bipolar I disorder. Population pharmacokinetic models for olanzapine and samidorphan were dev
Autor:
Andrew M. Atz, Susan Lin, Casey E Gelber, Daniel Gonzalez, Kevin M. Watt, Amira Al-Uzri, Michelle Adu-Darko, Chiara Melloni, Elizabeth H Payne, Janice E. Sullivan, Christoph P. Hornik, Peter M. Mourani, David Speicher, Ram Yogev, Michael Cohen-Wolkowiez, Barrie Harper
Publikováno v:
J Clin Pharmacol
Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfuncti
Autor:
Sepideh Nemat, Liping Zhang, Susumu Nakahara, Italo Poggesi, Wangda Zhou, Dolly A. Parasrampuria, Carlos Appiani, Joseph Massarella
Publikováno v:
Journal of clinical pharmacology. 59(5)
Dacogen, the formulated product of the pharmaceutically active agent decitabine (5 aza-2'-deoxycytidine), is approved for treatment of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). The current analysis was performed to characteri
Autor:
Abdelali Daddaoua, Cristina Pérez Ramírez, Manuela Expósito Ruiz, Alberto Jiménez Morales, Carlos García Collado, Carolina Alarcón Payer, Juan Enrique Martínez de la Plata, Mar Maldonado-Montoro
Publikováno v:
Journal of clinical pharmacology. 59(4)
We evaluated the influence of clinical, biochemical, and genetic factors on response in 142 patients diagnosed with rheumatoid arthritis, of whom 87 patients were treated with tocilizumab (61.26%) and 55 patients were treated with rituximab (38.7%;)
Publikováno v:
Journal of Clinical Pharmacology
CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysp
Publikováno v:
Journal of clinical pharmacology. 59(1)
Acetaminophen (APAP)-induced liver injury is initiated by metabolism of APAP by the cytochrome P-450 (CYP) system, primarily CYP2E1. We previously demonstrated CYP inhibition following administration of a liquid APAP formulation containing propylene